High ESRP2 expression was not prognostic of disease progression in the TCGA (PRostate ADenocarcinoma) PRAD cohort analysed using KM-express (Chen et al., 2018), but high expression of ESRP1 associated with a significantly reduced time to first biochemical recurrence (p=0.022) (Figure 2D). The gene discussed is ESRP2; the disease is prostate adenocarcinoma.